我们正在寻找中国人参与临床研究
News
AKL & HAM - 0800 788 3437
CHC & WLG - 0800 862 278

Important Information

If you are interested in applying for this study, please:
  • Read the study description and study information document.
  • Review the Visit Planner dates in your location and confirm that you are available for the stated dates.
  • If you have not yet registered with us, click on the ‘Register’ button at the top of this page and answer the questions.
  • If you have already registered with us, answer the pre-screening questions listed below and submit your interest.

We will then contact you to check your suitability.

Study Information

New Zealand Clinical Research is trialling an investigational medicine that could help people with obesity.

Worldwide, obesity and type 2 diabetes effects approximately 12% of adults. This rate continues to grow every year. The two conditions are closely linked and can lead to serious consequences and an array of metabolic, cardiovascular, and other conditions. This impacts the health-associated quality of life and is of significant cost for healthcare systems around the world.

Lifestyle modification, including diet, exercise, and behavioural change, remain key in the initial management of obesity. Any weight loss achieved with lifestyle interventions alone is challenging to maintain.

The study medicine, ARO-INHBE, is being investigated to see if it can help people with obesity by targeting the liver cells to reduce Activin E protein levels. This protein is involved in the regulation of fat (lipid) storage and breakdown of fat in the tissue (lipolysis). It is hoped that ARO-INHBE may reduce fat storage and improve fat breakdown in the body and improve blood sugar levels in people with obesity. Utilising a combination treatment approach with GLP-1 drugs, ARO-INHBE is being evaluated to determine whether it can provide an improved side effect profile and better health outcome for people affected by this condition.

This is an investigational medicine because it has not been approved by MedSafe or other drug regulatory authorities.

This study (2024 FULL 21128) is being funded by Arrowhead Pharmaceuticals, Inc and has been approved by the Health and Disability Ethics Committee.

Requirements

Healthy Males and Females

  • Diagnosis of Type 2 Diabetes (Managed by lifestyle, Metformin, or Jardiance.)
  • Aged between 18 – 65 years
  • BMI (Body Mass Index) between 30 – 50 kg/m²
  • Non-smokers or ex-smokers
  • Weigh up to 159 kgs
  • Medications allowed
  • Have at least one unsuccessful attempt to lose weight via lifestyle changes (e.g. reduced calorie diets, increasing exercise, etc.).

What is Involved?

Study Visits: 13 clinic visits.

Reimbursement: Up to $5,500 before tax.

Important Documents

Important documents to download and read

Pre-screening Form

Nexus - Type 2 Diabetes

Pre screening for Nexus Part 2 Type 2 Diabetes

Personal details

Please provide your name, email and phone number so we can contact you
NZCR Site(Required)
Which site are you located?

Medical questions

Have you tried to lose weight in the past?(Required)
What methods have you tried to lose weight in the past?
Smoking/Vaping History(Required)
The study does not accept any current smokers or vapers. Have you used any nicotine or tobacco containing products in the last 3 months?
What is your current height in centimeters?
Please enter a number from 100 to 250.
What is your current weight? Maximum weight: 159kg.
Please enter a number less than or equal to 159.

BMI Disclamer

To be suitable for this study, your BMI must fall within the range of 30 kg/m^2 and 50 kg/m^2. If your BMI is below 30 kg/m^2, or above 50 kg/m^2, you will not be considered for participation. Please check your BMI and ensure it is within that range before continuing with this form.
Do you have any history of medical conditions relating to:(Required)
Contraception(Required)
Please select the option describes your situation best:
Have you received blood or plasma in the last 56 days? If yes please provide details
Have you received any vaccinations in the last 14 days?
Do you have a history of Diabetes?(Required)
Please note: A diagnosis of Type 2 Diabetes is required to participate
Do you have any history of allergies, asthma, hay fever, food allergies etc that you are aware of? If yes to allergies, please indicate the severity of the reaction.
Any significant history of acid reflux or peptic (stomach) ulcers?
Do you have any history of clinically significant acute systemic infection and/or antibiotic treatment within 28 days?
Have you been sick in the last 30 days?
Have you ever undergone any gastric or intestinal surgery? This includes, but is not limited to, gastric bypass, gastric sleeve, gastric balloon, abdominoplasty (tummy tuck), or adjustable gastric band (lap band).
Have you taken any prescription, vitamins, supplements, pharmacy or over the counter medications in the last 28 days (please include any vaccines in the last 3 months as well)? If yes, please list out all the medications you are currently taking: some are exclusionary, so having this list will allow us to get back to you in a more accurate and timelier manner
Given this study is dose-on-demand, or you will be dosed with the study medication after completing the screening process, would you be available for weekly visits for the next 6 months?
Just to inform you, that you come in for screening at risk. There is no payment for the screening visit, and you may not be offered a position on the study if the group fills up, or you may only be offered a position as a back-up. It is not guaranteed that you will get a full position on the study as it depends on your results as well. Are you comfortable with this?
Pre-screening form policy(Required)
I understand that by submitting this form, NZCR will use the information for pre-screening purposes for this study. This information may be recorded on your profile to allow us to improve our process when screening you for a future study. All information provided is confidential. I also understand that by submitting this form, I will be receiving emails, texts or calls about this study. For more information, please refer to the Privacy Policy.